C3 activation is inhibited by analogs of compstatin but not by serine protease inhibitors or peptidyl α-ketoheterocycles

Immunopharmacology

Volumn 48, Issue 2, 2000, Pages 199-212

  Furlong, Stephen T ^a   Dutta, Anand S ^a   Coath, Matthew M ^a   Gormley, James J ^a   Hubbs, Stephen J ^a   Lloyd, Darleen ^a   Mauger, Russell C ^a   Strimpler, Anne M ^a   Sylvester, Mark A ^a   Scott, Clay W ^a   Edwards, Philip D ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

C3; C3 convertase; Complement; Compstatin

Indexed keywords

CLASSICAL COMPLEMENT PATHWAY C3 C5 CONVERTASE; COMPLEMENT COMPONENT C3; COMPLEMENT INHIBITOR; HETEROCYCLIC COMPOUND; PEPTIDE DERIVATIVE; SERINE PROTEINASE INHIBITOR;

ANIMAL CELL; ARTICLE; COMPLEMENT ACTIVATION; CONTROLLED STUDY; CYTOTOXICITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C3-C5 CONVERTASES; COMPLEMENT FACTOR B; COMPLEMENT INACTIVATOR PROTEINS; HEMOLYSIS; HUMANS; IMMUNOENZYME TECHNIQUES; PEPTIDES, CYCLIC; SERINE PROTEINASE INHIBITORS;

EID: 0034691542     PISSN: 01623109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0162-3109(00)00205-8     Document Type: Article

References (49)

1. Asghar S.S. Pharmacological manipulation of the complement system in human diseases. Front Biosci. 1:1996;e15-e25.
2. Berger A., Schechter I. Mapping the active site of papain with the aid of peptide substrates and inhibitors. Philos. Trans. R. Soc. London, Ser. B. 257:1970;249-264.
3. Boyum A. Isolation of mononuclear cells and granulocytes from human blood. Isolation of mononuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g. Scand. J. Clin. Lab. Invest. 21(97):1968;77-89.
4. Caporale L.H., Gaber S.S., Kell W., Gotze O. A fluorescent assay for complement activation. J. Immunol. 126:1981;1963-1965.
5. Cole L.B., Kilpatrick J.M., Chu N., Babu Y.S. Structure of 3,4-dichloroisocoumarin-inhibited factor D. Acta Crystallogr., Sect. D: Biol. Crystallogr. 54(5):1998;711-717.
6. Costanzo M.J., Maryanoff B.E., Hecker L.R., Schott M.R., Yabut S.C., Zhang H.C., Andrade-Gordon P., Kauffman J.A., Lewis J.M., Krishnan R., Tulinsky A. Potent thrombin inhibitors that probe the S1 subsite: tripeptide transition state analogues based on a heterocycle-activated carbonyl group. J. Med. Chem. 39:1996;3039-3043.
7. de Bruijn M.H., Fey G.H. Human complement component C3: cDNA coding sequence and derived primary structure. Proc. Natl. Acad. Sci. U.S.A. 82:1985;708-712.
8. Dodds A.W. Small-scale preparation of complement components C3 and C4. Methods Enzymol. 223:1993;46-61.
9. Drapeau G., Audet R., Levesque L., Godin D., Marceau F. Development and in vivo evaluation of metabolically resistant antagonists of B1 receptors for kinins. J. Pharmacol. Exp. Ther. 266:1993;192-199.
10. Dutta A.S., Gormley J.J., McLachlan P.F., Woodburn J.R. Conformationally restrained cyclic peptides as antagonists of luteinizing hormone-releasing hormone. Biochem. Biophys. Res. Commun. 159:1989;1114-1120.
11. Dutta A.S., Gormley J.J., McLachlan P.F., Major J.S. Novel inhibitors of human renin. Cyclic peptides based on the tetrapeptide sequence Glu-D-Phe-Lys-D-Trp. J. Med. Chem. 33:1990;2552-2560.
12. Edwards P.D., Bernstein P.R. Synthetic inhibitors of elastase. Med. Res. Rev. 14:1994;127-194.
13. Edwards P.D., Meyer E.F.Jr., Vijayalakshmi J., Tuthill P.A., Andisik D.A., Gomes B., Strimpler A. Design, synthesis and kinetic evaluation of a unique class of elastase inhibitors, the peptidyl α-ketobenzoxazoles, and the X-ray crystal structure of the covalent complex between porcine pancreatic elastase and Ac-Ala-Pro-Val-2-benzoxazole. J. Am. Chem. Soc. 114:1992;1854-1863.
14. Edwards P.D., Wolanin D.J., Andisik D.W., Davis M.W. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase: 2. Effect of varying the heterocyclic ring on in vitro potency. J. Med. Chem. 38:1995a;76-85.
15. Edwards P.D., Zottola M.A., Davis M., Williams J., Tuthill P.A. Peptidyl alpha-ketoheterocyclic inhibitors of human neutrophil elastase: 3. In vitro and in vivo potency of a series of peptidyl alpha-ketobenzoxazoles. J. Med. Chem. 38:1995b;3972-3982.
16. Ember J.A., Hugli T.E. Complement factors and their receptors. Immunopharmacology. 38:1997;3-15.
17. English D., Andersen B.R. Single-step separation of red blood cells. Granulocytes and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J. Immunol. Methods. 5:1974;249-252.
18. Fiane A.E., Mollnes T.E., Videm V., Hovig T., Hogasen K., Mellbye O.J., Spruce L., Moore W.T., Sahu A., Lambris J.D. Compstatin, a peptide inhibitor of C3, prolongs survival of ex vivo perfused pig xenografts. Xenotransplantation. 6:1999a;52-65.
19. Fiane A.E., Mollnes T.E., Videm V., Hovig T., Hogasen K., Mellbye O.J., Spruce L., Moore W.T., Sahu A., Lambris J.D. Prolongation of ex vivo-perfused pig xenograft survival by the complement inhibitor compstatin. Transplant. Proc. 31:1999b;934-935.
20. Gutierrez J.C., Gotze O., Caporale L.H. An improved fluorogenic substrate for the alternative complement pathway C3/5 converting enzyme CVFBb. Biochim. Biophys. Acta. 744:1983;276-280.
21. Heavner G.A., Kroon D.J., Audhya T., Goldstein G. Biologically active analogs of thymopentin with enhanced enzymatic stability. Peptides. 7:1986;1015-1019.
22. Hensley P., O'Keefe M.C., Spangler C.J., Osborne J.C. Jr., Vogel C.W. The effects of metal ions and temperature on the interaction of cobra venom factor and human complement factor B. J. Biol. Chem. 261:1986;11038-11044.
23. Jones L.J., Upson R.H., Haugland R.P., Panchuk-Voloshina N., Zhou M., Haugland R.P. Quenched BODIPY dye-labeled casein substrates for the assay of protease activity by direct fluorescence measurement. Anal. Biochem. 251:1997;144-152.
24. Kam C.M., Oglesby T.J., Pangburn M.K., Volanakis J.E., Powers J.C. Substituted isocoumarins as inhibitors of complement serine proteases. J. Immunol. 149:1992;163-168.
25. Kerr M.A. Factor B and the alternative pathway C3/C5 convertase. Barrett A.J., Rawlings N.D., Woessner J.F. Handbook of Proteolytic Enzymes. 1998;135-140 Academic Press, NY.
26. Kirschfink M. Controlling the complement system in inflammation. Immunopharmacology. 38:1997;51-62.
27. Lambris, J.D., 1997. Novel peptides which inhibit complement activation, University of Pennsylvania, publication date 18 Sept 1997. WO 97/33603 [WO 97/33603], 97, pp. 9-18.
28. Liszewski M.K., Farries T.C., Lublin D.M., Rooney I.A., Atkinson J.P. Control of the complement system. Adv. Immunol. 61:1996;201-283.
29. Makrides S.C. Therapeutic inhibition of the complement system. Pharmacol. Rev. 50:1998;59-87.
30. Moore F.D. Jr. Therapeutic regulation of the complement system in acute injury states. Adv. Immunol. 56:1994;267-299.
31. Morikis D., Assa-Munt N., Sahu A., Lambris J.D. Solution structure of compstatin, a potent complement inhibitor. Protein Sci. 7:1998;619-627.
32. Morikis, D., et al., 1999. Solution structure of Compstatin, a potent complement inhibitor. Protein Sci., 1998, Mar. 7, 619-27. XXIDS-PMID.
33. Nilsson B., Larsson R., Hong J., Elgue G., Ekdahl K.N., Sahu A., Lambris J.D. Compstatin inhibits complement and cellular activation in whole blood in two models of extracorporeal circulation. Blood. 92:1998;1661-1667.
34. Pangburn M.K. A fluorimetric assay for native C3. The hemolytically active form of the third component of human complement. J. Immunol. Methods. 102:1987;7-14.
35. Pangburn M.K., Muller-Eberhard H.J. Initiation of the alternative complement pathway due to spontaneous hydrolysis of the thioester of C3. Ann. N. Y. Acad. Sci. 421:1983;291-298.
36. Pangburn M.K., Muller-Eberhard H.J. The C3 convertase of the alternative pathway of human complement. Enzymic properties of the bimolecular proteinase. Biochem. J. 235:1986;723-730.
37. Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Formation of the initial C3 convertase of the alternative complement pathway. Acquisition of C3b-like activities by spontaneous hydrolysis of the putative thioester in native C3. J. Exp. Med. 154:1981;856-867.
38. Papadopoulos N.G., Dedoussis G.V., Spanakos G., Gritzapis A.D., Baxevanis C.N., Papamichail M. An improved fluorescence assay for the determination of lymphocyte-mediated cytotoxicity using flow cytometry. J. Immunol. Methods. 177:1994;101-111.
39. Pryzdial E.L., Isenman D.E. A reexamination of the role of magnesium in the human alternative pathway of complement. Mol. Immunol. 23:1986;87-96.
40. Reed B.M. The complement system. Hames B.D., Glover D.M. Molecular Immunology. 1995;326-381 Oxford Univ. Press, London.
41. Sahu A., Kay B.K., Lambris J.D. Inhibition of human complement by a C3-binding peptide isolated from a phage-displayed random peptide library. J. Immunol. 157:1996;884-891.
42. Sahu A., Pangburn M.K. Investigation of mechanism-based inhibitors of complement targeting the activated thioester of human C3. Biochem. Pharmacol. 51:1996;797-804.
43. Samanen J., Narindray D., Adams W. Jr., Cash T., Yellin T., Regoli D. Effects of D-amino acid substitution on antagonist activities of angiotensin II analogues. J. Med. Chem. 31:1988;510-516.
44. Sanchez-Corral P., Anton L.C., Alcolea J.M., Marques G., Sanchez A., Vivanco F. Proteolytic activity of the different fragments of factor B on the third component of complement (C3). Involvement of the N-terminal domain of Bb in magnesium binding. Mol. Immunol. 27:1990;891-900.
45. Soames C.J., Sim R.B. Interactions between human complement components factor H, factor I and C3b. Biochem. J. 326(2):1997;553-561.
46. Speth C., Wurzner R., Stoiber H., Dierich M.P. The complement system: pathophysiology and clinical relevance. Wien. Klin. Wochenschr. 111:1999;378-391.
47. Tennant J.R. Evaluation of the trypan blue technique for evaluation of cell viability. Transplantation. 2:1968;685-694.
48. Vogel C.W., Muller-Eberhard H.J. The cobra venom factor-dependent C3 convertase of human complement. A kinetic and thermodynamic analysis of a protease acting on its natural high molecular weight substrate. J. Biol. Chem. 257:1982;8292-8299.
49. Wang X.M., Terasaki P.I., Rankin G.W. Jr., Chia D., Zhong H.P., Hardy S. A new microcellular cytotoxicity test based on calcein AM release. Hum. Immunol. 37:1993;264-270.